Advertisement
U.S. markets open in 6 hours 41 minutes

Catalyst Pharmaceuticals, Inc. (CPRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
16.08+0.01 (+0.06%)
At close: 04:00PM EDT
15.80 -0.28 (-1.74%)
After hours: 07:50PM EDT

Catalyst Pharmaceuticals, Inc.

355 Alhambra Circle
Suite 801
Coral Gables, FL 33134
United States
305 420 3200
https://www.catalystpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees167

Key Executives

NameTitlePayExercisedYear Born
Mr. Patrick J. McEnanyCo-Founder & Chairman1.2MN/A1947
Mr. Richard John Daly M.B.A.President, CEO & Director63.12kN/A1961
Dr. Steven R. Miller Ph.D.Executive VP, COO & Chief Scientific Officer809.03kN/A1962
Dr. Gary Ingenito M.D., Ph.D.Chief Medical & Regulatory Officer751.85kN/A1956
Mr. Jeffrey Del CarmenExecutive VP & Chief Commercial Officer711.7kN/A1971
Mr. Michael W. Kalb CPAExecutive VP & CFON/AN/A1971
Ms. Mary ColemanVP & Head of Investor RelationsN/AN/AN/A
Mr. Brian Elsbernd J.D.Chief Compliance Officer & Chief Legal Officer311.42kN/A1964
Mr. Pete Curry Sr.Vice President of SalesN/AN/AN/A
Dr. Stanley Iyadurai M.D., Ph.D.Senior Vice President of Medical Affairs & Drug DiscoveryN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Corporate Governance

Catalyst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 5. The pillar scores are Audit: 9; Board: 4; Shareholder Rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.